Semax

Overview

Semax is a synthetic peptide analog of ACTH(4-10) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is approved in Russia and some CIS countries as a nootropic and neuroprotective agent for conditions including stroke recovery and cognitive impairment. It has not undergone Western regulatory evaluation.

Mechanism of Action

Semax is proposed to act through melanocortin receptor modulation (as an ACTH fragment), BDNF upregulation, and dopaminergic/serotonergic system modulation. The neuroprotective mechanism may involve NGF and BDNF-mediated neuroplasticity pathways.

Evidence Base

Approved in Russia for clinical use (stroke, cognitive impairment, optic nerve disease). Published studies are primarily in Russian-language journals. No Western RCTs or FDA evaluation. Animal studies show neuroprotective effects. Small open-label human studies report cognitive improvements.

Safety Considerations

Approved for clinical use in Russia, suggesting a degree of evaluated safety in that regulatory framework. No Western regulatory evaluation. Administered intranasally. Long-term safety data outside Russian clinical experience is unavailable.

FAQ